-
1
-
-
84860896956
-
Marketed therapeutic antibodies compendium
-
Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415
-
(2012)
MAbs
, vol.4
, pp. 413-415
-
-
Reichert, J.M.1
-
2
-
-
25144485908
-
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
-
Larson RA, Sievers EL, Stadtmauer EA et al (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452
-
(2005)
Cancer
, vol.104
, pp. 1442-1452
-
-
Larson, R.A.1
Sievers, E.L.2
Stadtmauer, E.A.3
-
3
-
-
0035397980
-
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
-
Sievers EL, Larson RA, Stadtmauer EA et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol J Am Soc Clin Oncol 19:3244-3254
-
(2001)
J Clin Oncol J Am Soc Clin Oncol
, vol.19
, pp. 3244-3254
-
-
Sievers, E.L.1
Larson, R.A.2
Stadtmauer, E.A.3
-
4
-
-
80054113954
-
Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin
-
Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res J Am Assoc Cancer Res 17:6417-6427
-
(2011)
Clin Cancer Res J Am Assoc Cancer Res
, vol.17
, pp. 6417-6427
-
-
Ricart, A.D.1
-
5
-
-
74849092615
-
Antibody-drug conjugate targets
-
Teicher BA (2009) Antibody-drug conjugate targets. Curr Cancer Drug Targets 9:982-1004
-
(2009)
Curr Cancer Drug Targets
, vol.9
, pp. 982-1004
-
-
Teicher, B.A.1
-
6
-
-
3042736089
-
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors
-
Helft PR, Schilsky RL, Hoke FJ et al (2004) A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res J Am Assoc Cancer Res 10:4363-4368
-
(2004)
Clin Cancer Res J Am Assoc Cancer Res
, vol.10
, pp. 4363-4368
-
-
Helft, P.R.1
Schilsky, R.L.2
Hoke, F.J.3
-
7
-
-
0037440038
-
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study
-
Tolcher AW, Ochoa L, Hammond LA et al (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: A phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol J Am Soc Clin Oncol 21:211-222
-
(2003)
J Clin Oncol J Am Soc Clin Oncol
, vol.21
, pp. 211-222
-
-
Tolcher, A.W.1
Ochoa, L.2
Hammond, L.A.3
-
9
-
-
50049134725
-
Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
-
Riechelmann H, Sauter A, Golze W et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44:823-829
-
(2008)
Oral Oncol
, vol.44
, pp. 823-829
-
-
Riechelmann, H.1
Sauter, A.2
Golze, W.3
-
10
-
-
34247890107
-
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck
-
Sauter A, Kloft C, Gronau S et al (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30:927-935
-
(2007)
Int J Oncol
, vol.30
, pp. 927-935
-
-
Sauter, A.1
Kloft, C.2
Gronau, S.3
-
11
-
-
33750685640
-
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus
-
Tijink BM, Buter J, Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res J Am Assoc Cancer Res 12:6064-6072
-
(2006)
Clin Cancer Res J Am Assoc Cancer Res
, vol.12
, pp. 6064-6072
-
-
Tijink, B.M.1
Buter, J.2
Bree, R.3
-
12
-
-
84862162222
-
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
-
Lapusan S, Vidriales MB, Thomas X et al (2012) Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 30:1121-1131
-
(2012)
Invest New Drugs
, vol.30
, pp. 1121-1131
-
-
Lapusan, S.1
Vidriales, M.B.2
Thomas, X.3
-
13
-
-
84873614573
-
Preclinical evaluationof ananti-CD33-maytansinoidimmunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia
-
Abstract LB-287
-
Chari R, Xie H, Leece B (2005) Preclinical evaluationof ananti-CD33-maytansinoidimmunoconjugate, huMy9-6-DM4 (AVE9633) for the targeted therapy of acute myeloid leukemia.Am Assoc Cancer Res, Abstract LB-287
-
(2005)
Am Assoc Cancer Res
-
-
Chari, R.1
Xie, H.2
Leece, B.3
-
14
-
-
38949192547
-
Targeted cancer therapy: Conferring specificity to cytotoxic drugs
-
Chari RV (2008) Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 41:98-107
-
(2008)
Acc Chem Res
, vol.41
, pp. 98-107
-
-
Chari, R.V.1
-
16
-
-
67649886201
-
Potent antibody drug conjugates for cancer therapy
-
Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13:235-244
-
(2009)
Curr Opin Chem Biol
, vol.13
, pp. 235-244
-
-
Senter, P.D.1
-
17
-
-
0026593928
-
Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
-
Chari RV, Martell BA, Gross JL et al (1992) Immunoconjugates containing novel maytansinoids: Promising anticancer drugs. Cancer Res 52:127-131
-
(1992)
Cancer Res
, vol.52
, pp. 127-131
-
-
Chari, R.V.1
Martell, B.A.2
Gross, J.L.3
-
18
-
-
33745847797
-
Semisynthetic maytansine analogues for the targeted treatment of cancer
-
Widdison WC, Wilhelm SD, Cavanagh EE et al (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
-
(2006)
J Med Chem
, vol.49
, pp. 4392-4408
-
-
Widdison, W.C.1
Wilhelm, S.D.2
Cavanagh, E.E.3
-
19
-
-
31544441685
-
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
-
Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
-
(2006)
Bioconjug Chem
, vol.17
, pp. 114-124
-
-
Doronina, S.O.1
Mendelsohn, B.A.2
Bovee, T.D.3
-
20
-
-
0036007598
-
An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
-
Hamann PR, Hinman LM, Beyer CF et al (2002) An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 13:40-46
-
(2002)
Choice of linker. Bioconjug Chem
, vol.13
, pp. 40-46
-
-
Hamann, P.R.1
Hinman, L.M.2
Beyer, C.F.3
-
21
-
-
65549140215
-
Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies
-
Tietze LF, Krewer B (2009) Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agent Med Chem 9:304-325
-
(2009)
Anticancer Agent Med Chem
, vol.9
, pp. 304-325
-
-
Tietze, L.F.1
Krewer, B.2
-
22
-
-
74949107560
-
Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies
-
Ducry L, Stump B (2010) Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21:5-13
-
(2010)
Bioconjug Chem
, vol.21
, pp. 5-13
-
-
Ducry, L.1
Stump, B.2
-
23
-
-
33645500289
-
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
-
Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433
-
(2006)
Cancer Res
, vol.66
, pp. 4426-4433
-
-
Erickson, H.K.1
Park, P.U.2
Widdison, W.C.3
Kovtun, Y.V.4
Garrett, L.M.5
Hoffman, K.6
Lutz, R.J.7
Goldmacher, V.S.8
Blattler, W.A.9
-
24
-
-
10744222473
-
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
-
Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784
-
(2003)
Nat Biotechnol
, vol.21
, pp. 778-784
-
-
Doronina, S.O.1
Toki, B.E.2
Torgov, M.Y.3
-
25
-
-
74949139946
-
Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
-
Erickson HK, Widdison WC, Mayo MF et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92
-
(2010)
Bioconjug Chem
, vol.21
, pp. 84-92
-
-
Erickson, H.K.1
Widdison, W.C.2
Mayo, M.F.3
-
26
-
-
79955022475
-
Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage
-
Kellogg BA, Garrett L, Kovtun Y et al (2011) Disulfide-linked antibody-maytansinoid conjugates: Optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22:717-727
-
(2011)
Bioconjug Chem
, vol.22
, pp. 717-727
-
-
Kellogg, B.A.1
Garrett, L.2
Kovtun, Y.3
-
28
-
-
33644787435
-
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
-
Kovtun YV, Audette CA, Ye Y et al (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214-3221
-
(2006)
Cancer Res
, vol.66
, pp. 3214-3221
-
-
Kovtun, Y.V.1
Audette, C.A.2
Ye, Y.3
-
29
-
-
12244295755
-
In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate
-
Sanderson RJ, Hering MA, James SF et al (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res J Am Assoc Cancer Res 11:843-852
-
(2005)
Clin Cancer Res J Am Assoc Cancer Res
, vol.11
, pp. 843-852
-
-
Sanderson, R.J.1
Hering, M.A.2
James, S.F.3
-
30
-
-
6044223544
-
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
-
Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res J Am Assoc Cancer Res 10:7063-7070
-
(2004)
Clin Cancer Res J Am Assoc Cancer Res
, vol.10
, pp. 7063-7070
-
-
Hamblett, K.J.1
Senter, P.D.2
Chace, D.F.3
-
31
-
-
84863012529
-
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
-
Shen B, Xu K, Liu L et al (2012) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189
-
(2012)
Nat Biotechnol
, vol.30
, pp. 184-189
-
-
Shen, B.1
Xu, K.2
Liu, L.3
-
32
-
-
79952718320
-
Analytical methods for physicochemical characterization of antibody drug conjugates
-
Wakankar A, Chen Y, Gokarn Y et al (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 3:161-172
-
(2011)
MAbs
, vol.3
, pp. 161-172
-
-
Wakankar, A.1
Chen, Y.2
Gokarn, Y.3
-
33
-
-
80052076003
-
CD30: An important new target in hematologic malignancies
-
Deutsch YE, Tadmor T, Podack ER et al (2011) CD30: An important new target in hematologic malignancies. Leuk Lymphoma 52:1641-1654
-
(2011)
Leuk Lymphoma
, vol.52
, pp. 1641-1654
-
-
Deutsch, Y.E.1
Tadmor, T.2
Podack, E.R.3
-
34
-
-
77950099811
-
Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma
-
Gerber H (2010) Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 79:1544-1552
-
(2010)
Biochem Pharmacol
, vol.79
, pp. 1544-1552
-
-
Gerber, H.1
-
36
-
-
80054111050
-
CD30-targeted antibody therapy
-
Younes A (2011) CD30-targeted antibody therapy. Curr Opin Oncol 23:587-593
-
(2011)
Curr Opin Oncol
, vol.23
, pp. 587-593
-
-
Younes, A.1
-
37
-
-
84856998215
-
Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: Focus on brentuximab vedotin
-
Furtado M, Rule S (2012) Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: Focus on brentuximab vedotin. Clin Med Insight Oncol 6:31-39
-
(2012)
Clin Med Insight Oncol
, vol.6
, pp. 31-39
-
-
Furtado, M.1
Rule, S.2
-
38
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
-
Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol J Am Soc Clin Oncol 30:2190-2196
-
(2012)
J Clin Oncol J Am Soc Clin Oncol
, vol.30
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
-
39
-
-
84863688504
-
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
-
Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30:631-637
-
(2012)
Nat Biotechnol
, vol.30
, pp. 631-637
-
-
Senter, P.D.1
Sievers, E.L.2
-
40
-
-
0042738861
-
Cac10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
-
Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465
-
(2003)
Blood
, vol.102
, pp. 1458-1465
-
-
Francisco, J.A.1
Cerveny, C.G.2
Meyer, D.L.3
-
41
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
-
(2010)
N Engl J Med
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
Bartlett, N.L.2
Leonard, J.P.3
-
42
-
-
84855465227
-
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies
-
Fanale MA, Forero-Torres A, Rosenblatt JD et al (2012) A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res J Am Assoc Cancer Res 18:248-255
-
(2012)
Clin Cancer Res J Am Assoc Cancer Res
, vol.18
, pp. 248-255
-
-
Fanale, M.A.1
Forero-Torres, A.2
Rosenblatt, J.D.3
-
43
-
-
84863676500
-
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin and other lymphoma
-
Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin and other lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2183-2189
-
(2012)
J Clin Oncol J Am Soc Clin Oncol
, vol.30
, pp. 2183-2189
-
-
Younes, A.1
Gopal, A.K.2
Smith, S.E.3
-
44
-
-
84858032909
-
Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma
-
Minich SS (2012) Brentuximab vedotin: A new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma. Ann Pharmacother 46:377-383
-
(2012)
Ann Pharmacother
, vol.46
, pp. 377-383
-
-
Minich, S.S.1
-
45
-
-
0028670125
-
The biology of erbB-2/neu/HER-2 and its role in cancer
-
Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198:165-184
-
(1994)
Biochim Biophys Acta
, vol.1198
, pp. 165-184
-
-
Hynes, N.E.1
Stern, D.F.2
-
46
-
-
73949090721
-
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review
-
Dawood S, Broglio K, Buzdar AU et al (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol J Am Soc Clin Oncol 28:92-98
-
(2010)
J Clin Oncol J Am Soc Clin Oncol
, vol.28
, pp. 92-98
-
-
Dawood, S.1
Broglio, K.2
Buzdar, A.U.3
-
47
-
-
84655162706
-
Treatment of HER2-positive breast cancer: Current status and future perspectives
-
Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat Rev Clin Oncol 9:16-32
-
(2012)
Nat Rev Clin Oncol
, vol.9
, pp. 16-32
-
-
Arteaga, C.L.1
Sliwkowski, M.X.2
Osborne, C.K.3
-
48
-
-
84855406013
-
Beyond trastuzumab: Novel therapeutic strategies in HER2-positive metastatic breast cancer
-
Tsang RY, Finn RS (2012) Beyond trastuzumab: Novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer 106:6-13
-
(2012)
Br J Cancer
, vol.106
, pp. 6-13
-
-
Tsang, R.Y.1
Finn, R.S.2
-
49
-
-
56449129810
-
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
-
Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290
-
(2008)
Cancer Res
, vol.68
, pp. 9280-9290
-
-
Phillips, G.D.1
Li, G.2
Dugger, D.L.3
-
50
-
-
79959700509
-
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
-
Junttila TT, Li G, Parsons K et al (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347-356
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 347-356
-
-
Junttila, T.T.1
Li, G.2
Parsons, K.3
-
51
-
-
84860389569
-
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo
-
Barok M, Tanner M, Koninki K et al (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res BCR 13:R46
-
(2011)
Breast Cancer Res BCR
, vol.13
-
-
Barok, M.1
Tanner, M.2
Koninki, K.3
-
52
-
-
77954031486
-
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
-
Krop IE, Beeram M, Modi S et al (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol J Am Soc Clin Oncol 28:2698-2704
-
(2010)
J Clin Oncol J Am Soc Clin Oncol
, vol.28
, pp. 2698-2704
-
-
Krop, I.E.1
Beeram, M.2
Modi, S.3
-
53
-
-
84869508508
-
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
-
Beeram M, Krop IE, Burris HA et al (2012) A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118:5733-5740
-
(2012)
Cancer
, vol.118
, pp. 5733-5740
-
-
Beeram, M.1
Krop, I.E.2
Burris, H.A.3
-
54
-
-
80054989315
-
Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2+ breast cancer
-
Burris HA, Tibbitts J, Holden SN et al (2011) Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2+ breast cancer. Clin Breast Cancer 11:275-282
-
(2011)
Clin Breast Cancer
, vol.11
, pp. 275-282
-
-
Burris, H.A.1
Tibbitts, J.2
Holden, S.N.3
-
55
-
-
80054109854
-
Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: A review
-
Mathew J, Perez EA (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: A review. Curr Opin Oncol 23:594-600
-
(2011)
Curr Opin Oncol
, vol.23
, pp. 594-600
-
-
Mathew, J.1
Perez, E.A.2
-
56
-
-
80054092983
-
Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer
-
Lorusso PM, Weiss D, Guardino E et al (2011) Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res J Am Assoc Cancer Res 17:6437-6447
-
(2011)
Clin Cancer Res J Am Assoc Cancer Res
, vol.17
, pp. 6437-6447
-
-
Lorusso, P.M.1
Weiss, D.2
Guardino, E.3
-
57
-
-
79952092706
-
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy
-
Burris HA, Rugo HS, Vukelja SJ et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol J Am Soc Clin Oncol 29:398-405
-
(2011)
J Clin Oncol J Am Soc Clin Oncol
, vol.29
, pp. 398-405
-
-
Burris, H.A.1
Rugo, H.S.2
Vukelja, S.J.3
-
58
-
-
84863688392
-
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine
-
Krop IE, Lorusso P, Miller KD et al (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol J Am Soc Clin Oncol 30:3234-3241
-
(2012)
J Clin Oncol J Am Soc Clin Oncol
, vol.30
, pp. 3234-3241
-
-
Krop, I.E.1
Lorusso, P.2
Miller, K.D.3
-
59
-
-
84862228236
-
Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer
-
Girish S, Gupta M, Wang B et al (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69:1229-1240
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1229-1240
-
-
Girish, S.1
Gupta, M.2
Wang, B.3
-
60
-
-
84860307997
-
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer
-
Gupta M, Lorusso PM, Wang B et al (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691-703
-
(2012)
J Clin Pharmacol
, vol.52
, pp. 691-703
-
-
Gupta, M.1
Lorusso, P.M.2
Wang, B.3
-
61
-
-
79551609265
-
Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g
-
viii2, Abstract LBA3
-
Perez E, Dirix L, Kocsis J et al (2010) Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: Preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450g). Ann Oncol 21(Suppl 8):viii2, Abstract LBA3
-
(2010)
Ann Oncol
, vol.21
, Issue.SUPPL.8
-
-
Perez, E.1
Dirix, L.2
Kocsis, J.3
-
62
-
-
83255175479
-
Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976
-
ECCO-ESMO, Abstract 5001
-
Hurvitz S, Dirix L, Kocsis J et al (2011) Trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (H + T) in previouslyuntreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/B021976). Eur J Cancer 47:ECCO-ESMO, Abstract 5001
-
(2011)
Eur J Cancer
, vol.47
-
-
Hurvitz, S.1
Dirix, L.2
Kocsis, J.3
-
63
-
-
84868520609
-
Trastuzumab emtansine for HER2-positive advanced breast cancer
-
Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791
-
(2012)
N Engl J Med
, vol.367
, pp. 1783-1791
-
-
Verma, S.1
Miles, D.2
Gianni, L.3
-
64
-
-
26644450721
-
CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction
-
Tedder TF, Poe JC, Haas KM (2005) CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1-50
-
(2005)
Adv Immunol
, vol.88
, pp. 1-50
-
-
Tedder, T.F.1
Poe, J.C.2
Haas, K.M.3
-
65
-
-
0029025026
-
Constitutive endocytosis and degradation of CD22 by human B cells
-
Shan D, Press OW (1995) Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466-4475
-
(1995)
J Immunol
, vol.154
, pp. 4466-4475
-
-
Shan, D.1
Press, O.W.2
-
66
-
-
77954681710
-
Inotuzumab ozogamicin as novel therapy in lymphomas
-
Wong BY, Dang NH (2010) Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 10:1251-1258
-
(2010)
Expert Opin Biol Ther
, vol.10
, pp. 1251-1258
-
-
Wong, B.Y.1
Dang, N.H.2
-
67
-
-
84861040649
-
Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
-
Thomas X (2012) Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 21:871-878
-
(2012)
Expert Opin Investig Drugs
, vol.21
, pp. 871-878
-
-
Thomas, X.1
-
68
-
-
4544320025
-
Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma
-
DiJoseph JF, Goad ME, Dougher MM et al (2004) Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 10:8620-8629
-
(2004)
Clin Cancer Res J Am Assoc Cancer Res
, vol.10
, pp. 8620-8629
-
-
DiJoseph, J.F.1
Goad, M.E.2
Dougher, M.M.3
-
69
-
-
77951648118
-
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin and other lymphoma: Results of a phase I study
-
Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin and other lymphoma: Results of a phase I study. J Clin Oncol J Am Soc Clin Oncol 28:2085-2093
-
(2010)
J Clin Oncol J Am Soc Clin Oncol
, vol.28
, pp. 2085-2093
-
-
Advani, A.1
Coiffier, B.2
Czuczman, M.S.3
-
70
-
-
77954839504
-
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximabbased therapy
-
Ogura M, Tobinai K, Hatake K et al (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximabbased therapy. Cancer Sci 101:1840-1845
-
(2010)
Cancer Sci
, vol.101
, pp. 1840-1845
-
-
Ogura, M.1
Tobinai, K.2
Hatake, K.3
-
71
-
-
31544455876
-
Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
-
DiJoseph JF, Dougher MM, Kalyandrug LB et al (2006) Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res J Am Assoc Cancer Res 12:242-249
-
(2006)
Clin Cancer Res J Am Assoc Cancer Res
, vol.12
, pp. 242-249
-
-
DiJoseph, J.F.1
Dougher, M.M.2
Kalyandrug, L.B.3
-
72
-
-
77953682059
-
Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity including survival in patients with recurrent/refractory follicular or "aggressive" lymphoma
-
Abstract 584
-
Dang N, Smith M, Offner F et al (2009) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity including survival in patients with recurrent/refractory follicular or "aggressive" lymphoma. Blood 114, Abstract 584
-
(2009)
Blood
, vol.114
-
-
Dang, N.1
Smith, M.2
Offner, F.3
-
73
-
-
67650873888
-
Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1/2 study
-
Abstract 266
-
Fayad L, Patel H, Verhoef G et al (2008) Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: Preliminary report of a phase 1/2 study. Blood 112, Abstract 266
-
(2008)
Blood
, vol.112
-
-
Fayad, L.1
Patel, H.2
Verhoef, G.3
-
74
-
-
80054122516
-
Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity in patients with relapsed/refractory follicular or aggressive lymphomas
-
Abstract 0573
-
Verhoef G, Dang N, Smith M et al (2010) Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity in patients with relapsed/refractory follicular or aggressive lymphomas. Haematologica 95, Abstract 0573
-
(2010)
Haematologica
, vol.95
-
-
Verhoef, G.1
Dang, N.2
Smith, M.3
-
75
-
-
80054113336
-
Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL
-
Abstract 6507
-
Jabbour E, O'Brien S, Thomas DA, Ravandi F et al (2011) Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J Clin Oncol 29, Abstract 6507
-
(2011)
J Clin Oncol
, vol.29
-
-
Jabbour, E.1
O'Brien, S.2
Thomas, D.A.3
Ravandi, F.4
-
76
-
-
84862786326
-
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study
-
Kantarjian H, Thomas D, Jorgensen J et al (2012) Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study. Lancet Oncol 13:403-411
-
(2012)
Lancet Oncol
, vol.13
, pp. 403-411
-
-
Kantarjian, H.1
Thomas, D.2
Jorgensen, J.3
-
77
-
-
80054095609
-
SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies
-
Blanc V, Bousseau A, Caron A et al (2011) SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res J Am Assoc Cancer Res 17:6448-6458
-
(2011)
Clin Cancer Res J Am Assoc Cancer Res
, vol.17
, pp. 6448-6458
-
-
Blanc, V.1
Bousseau, A.2
Caron, A.3
-
78
-
-
84864544136
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma
-
Younes A, Kim S, Romaguera J et al (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma. J Clin Oncol J Am Soc Clin Oncol 30:2776-2782
-
(2012)
J Clin Oncol J Am Soc Clin Oncol
, vol.30
, pp. 2776-2782
-
-
Younes, A.1
Kim, S.2
Romaguera, J.3
-
79
-
-
84866529248
-
Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731
-
Abstract 8057
-
Coiffier B, Morschhauser F, Dupuis J et al (2012) Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma (NCT00796731). J Clin Oncol 30, Abstract 8057
-
(2012)
J Clin Oncol
, vol.30
-
-
Coiffier, B.1
Morschhauser, F.2
Dupuis, J.3
-
80
-
-
84866559756
-
CD19 as an attractive target for antibody-based therapy
-
Hammer O (2012) CD19 as an attractive target for antibody-based therapy. MAbs 4:571-577
-
(2012)
MAbs
, vol.4
, pp. 571-577
-
-
Hammer, O.1
-
81
-
-
84855702068
-
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer
-
Keir CH, Vahdat LT (2012) The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 12:259-263
-
(2012)
Expert Opin Biol Ther
, vol.12
, pp. 259-263
-
-
Keir, C.H.1
Vahdat, L.T.2
-
82
-
-
33644747384
-
CR011, a fully human monoclonal antibody-Auristatin E conjugate, for the treatment of melanoma
-
Tse KF, Jeffers M, Pollack VA et al (2006) CR011, a fully human monoclonal antibody-Auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res J Am Assoc Cancer Res 12:1373-1382
-
(2006)
Clin Cancer Res J Am Assoc Cancer Res
, vol.12
, pp. 1373-1382
-
-
Tse, K.F.1
Jeffers, M.2
Pollack, V.A.3
-
83
-
-
77950835018
-
Glembatumumab vedotin, a conjugate of an antiglycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer
-
Naumovski L, Junutula JR (2010) Glembatumumab vedotin, a conjugate of an antiglycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248-257
-
(2010)
Curr Opin Mol Ther
, vol.12
, pp. 248-257
-
-
Naumovski, L.1
Junutula, J.R.2
-
84
-
-
79952646477
-
Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma
-
Abstract 8525
-
Hamid O, Sznol M, Pavlick A et al (2010) Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. J Clin Oncol 28, Abstract 8525
-
(2010)
J Clin Oncol
, vol.28
-
-
Hamid, O.1
Sznol, M.2
Pavlick, A.3
-
85
-
-
79952638233
-
Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma
-
Abstract 9063
-
Szol M, Hamid O, Hwu P et al (2009) Pharmacokinetics of CR011-vcMMAE, an antibody-drug conjugate, in a phase I study of patients with advanced melanoma. J Clin Oncol 27, Abstract 9063
-
(2009)
J Clin Oncol
, vol.27
-
-
Szol, M.1
Hamid, O.2
Hwu, P.3
-
86
-
-
84858205260
-
Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE
-
Abstract 1095
-
Saleh M, Bendell J, Rose et al (2010) Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CR011-vcMMAE). J Clin Oncol 28, Abstract 1095
-
(2010)
J Clin Oncol
, vol.28
-
-
Saleh, M.1
Bendell, J.2
Rose3
-
87
-
-
77952293797
-
Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein
-
Hoashi T, Sato S, Yamaguchi Y et al (2010) Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J 24:1616-1629
-
(2010)
FASEB J
, vol.24
, pp. 1616-1629
-
-
Hoashi, T.1
Sato, S.2
Yamaguchi, Y.3
-
88
-
-
80052665722
-
Prostate-specific membrane antigen-based therapeutics
-
Akhtar NH, Pail O, Saran A et al (2012) Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012:973820
-
(2012)
Adv Urol
, vol.2012
, pp. 973820
-
-
Akhtar, N.H.1
Pail, O.2
Saran, A.3
-
89
-
-
3843113671
-
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
-
Ghosh A, Heston WD (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539
-
(2004)
J Cell Biochem
, vol.91
, pp. 528-539
-
-
Ghosh, A.1
Heston, W.D.2
-
90
-
-
0033168844
-
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature
-
Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-Associated neovasculature. Cancer Res 59:3192-3198
-
(1999)
Cancer Res
, vol.59
, pp. 3192-3198
-
-
Chang, S.S.1
Reuter, V.E.2
Heston, W.D.3
-
91
-
-
78951476072
-
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer
-
Minner S, Wittmer C, Graefen M et al (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281-288
-
(2011)
Prostate
, vol.71
, pp. 281-288
-
-
Minner, S.1
Wittmer, C.2
Graefen, M.3
-
92
-
-
0031042591
-
Prostate-specific membrane antigen expression in normal and malignant human tissues
-
Silver DA, Pellicer I, Fair WR et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res J Am Assoc Cancer Res 3:81-85
-
(1997)
Clin Cancer Res J Am Assoc Cancer Res
, vol.3
, pp. 81-85
-
-
Silver, D.A.1
Pellicer, I.2
Fair, W.R.3
-
93
-
-
80052740269
-
In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatinconjugated antibody to prostate-specific membrane antigen
-
Wang X, Ma D, Olson WC et al (2011) In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatinconjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10:1728-1739
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1728-1739
-
-
Wang, X.1
Ma, D.2
Olson, W.C.3
-
94
-
-
43749092340
-
Phase I trial of the prostatespecific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
-
Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostatespecific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol J Am Soc Clin Oncol 26:2147-2154
-
(2008)
J Clin Oncol J Am Soc Clin Oncol
, vol.26
, pp. 2147-2154
-
-
Galsky, M.D.1
Eisenberger, M.2
Moore-Cooper, S.3
-
95
-
-
84881571812
-
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane
-
Abstract 107
-
Petrylak D, Kantoff P, Mega-A et al (2012) Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane. J Clin Oncol 30, Abstract 107
-
(2012)
J Clin Oncol
, vol.30
-
-
Petrylak, D.1
Kantoff, P.2
Mega, A.3
-
96
-
-
80052688423
-
Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer
-
Abstract 4550
-
Petrylak D, Kantoff P, Frank R et al (2011) Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. J Clin Oncol 29, Abstract 4550
-
(2011)
J Clin Oncol
, vol.29
-
-
Petrylak, D.1
Kantoff, P.2
Frank, R.3
-
97
-
-
84934441487
-
Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A phase 1 trial in castration-resistant metastatic prostate cancer (mCRPC
-
Petrylak D, Kantoff P, Mega-A et al (2012) Prostate specific membrane antigen antibody drug conjugate (PSMA ADC): A phase 1 trial in castration-resistant metastatic prostate cancer (mCRPC). EORTC-NCI-AACR 47
-
(2012)
EORTC-NCI-AACR
, vol.47
-
-
Petrylak, D.1
Kantoff, P.2
Mega, A.3
-
98
-
-
8944235348
-
A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
-
Wijdenes J, Vooijs WC, Clément C et al (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94:318-323
-
(1996)
Br J Haematol
, vol.94
, pp. 318-323
-
-
Wijdenes, J.1
Vooijs, W.C.2
Clément, C.3
-
99
-
-
9444223279
-
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
-
Tassone P, Goldmacher VS, Neri P et al (2004) Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104:3688-3696
-
(2004)
Blood
, vol.104
, pp. 3688-3696
-
-
Tassone, P.1
Goldmacher, V.S.2
Neri, P.3
-
100
-
-
80054050580
-
BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma
-
Abstract 305
-
Jagannath S, Chanan-Khan A, Heffner L et al (2011) BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in a phase I study in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting, Abstract 305
-
(2011)
ASH Annual Meeting
-
-
Jagannath, S.1
Chanan-Khan, A.2
Heffner, L.3
-
101
-
-
77953663858
-
Antibody-maytansinoid conjugates for the treatment of myeloma
-
Lutz RJ, Whiteman KR (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 1:548-551
-
(2009)
MAbs
, vol.1
, pp. 548-551
-
-
Lutz, R.J.1
Whiteman, K.R.2
-
102
-
-
78650263326
-
Phase I study of IMGN901, used as monotherapy, in patients with heavily pretreated CD56-positive multiple myeloma -A preliminary safety and efficacy analysis
-
Abstract 2883
-
Chanan-Khan A, Wolf J, Gharibo M. et al (2009) Phase I study of IMGN901, used as monotherapy, in patients with heavily pretreated CD56-positive multiple myeloma -A preliminary safety and efficacy analysis. ASH Annual Meeting, Abstract 2883
-
(2009)
ASH Annual Meeting
-
-
Chanan-Khan, A.1
Wolf, J.2
Gharibo, M.3
-
103
-
-
84908548836
-
Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC
-
Abstract B237
-
Woll P, Laurigan P, O'Brien M et al (2009) Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). Mol Cancer Ther 8, Abstract B237
-
(2009)
Mol Cancer Ther
, vol.8
-
-
Woll, P.1
Laurigan, P.2
O'Brien, M.3
-
104
-
-
84857344699
-
Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors
-
Abstract 536
-
Woll PJ, O'Brien M, Fossella F et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumors. Ann Oncol J Eur Soc Med Oncol ESMO, Abstract 536
-
(2010)
Ann Oncol J Eur Soc Med Oncol ESMO
-
-
Woll, P.J.1
O'Brien, M.2
Fossella, F.3
-
105
-
-
79960248682
-
Phase I study of lorvotuzumab mertansine (IMGN901) used in combination with lenalidomide and dexamethasone in patients with CD56-positive multiple myeloma, a preliminary safety and efficacy analysis of the combination
-
Abstract. 1934
-
Berdeja J, Ailawadhi S, Niesvizky R et al (2010) Phase I study of lorvotuzumab mertansine (IMGN901) used in combination with lenalidomide and dexamethasone in patients with CD56-positive multiple myeloma, a preliminary safety and efficacy analysis of the combination. ASHAnnual Meeting, Abstract 1934
-
(2010)
ASHAnnual Meeting
-
-
Berdeja, J.1
Ailawadhi, S.2
Niesvizky, R.3
-
106
-
-
84993814474
-
A single-Arm, open-label, multicenter phase I/ II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM
-
Abstract TPS8115
-
Berdeja J, Mace J, Lamar R et al (2012) A single-Arm, open-label, multicenter phase I/ II study of the combination of panobinostat (pan) and carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). J Clin Oncol 30, Abstract TPS8115
-
(2012)
J Clin Oncol
, vol.30
-
-
Berdeja, J.1
Mace, J.2
Lamar, R.3
-
107
-
-
84881587923
-
Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment
-
Abstract 4289
-
Mao W, Tien J, Goldenberg D et al (2010) Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment. Annual Meeting of the AACR, Abstract 4289
-
(2010)
Annual Meeting of the AACR
-
-
Mao, W.1
Tien, J.2
Goldenberg, D.3
-
109
-
-
84881598632
-
Ptk7 as a direct and tumor stroma target in multiple solid malignancies
-
Abstract 1526
-
Terrett J, Devasthali V, Pan C et al (2008) Ptk7 as a direct and tumor stroma target in multiple solid malignancies. Annual Meeting of the AACR, Abstract 1526
-
(2008)
Annual Meeting of the AACR
-
-
Terrett, J.1
Devasthali, V.2
Pan, C.3
-
110
-
-
84934436644
-
Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models
-
Vater C, Manning C, Millar H et al (2008) Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. EORTC-NCI-AACR, Abstract ENA-0399
-
(2008)
EORTC-NCI-AACR, Abstract ENA-0399
-
-
Vater, C.1
Manning, C.2
Millar, H.3
-
111
-
-
84866241140
-
High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production
-
Thon JN, Devine MT, Begonja AJ et al (2012) High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood 120:1975-1984
-
(2012)
Blood
, vol.120
, pp. 1975-1984
-
-
Thon, J.N.1
Devine, M.T.2
Begonja, A.J.3
-
112
-
-
77950224905
-
Antibody-maytansinoid conjugates designed to bypass multidrug resistance
-
Kovtun YV, Audette CA, Mayo MF et al (2010) Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70:2528-2537
-
(2010)
Cancer Res
, vol.70
, pp. 2528-2537
-
-
Kovtun, Y.V.1
Audette, C.A.2
Mayo, M.F.3
-
113
-
-
84869137056
-
ADME of antibody-maytansinoid conjugates
-
Erickson HK, Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14:799-805
-
(2012)
AAPS J
, vol.14
, pp. 799-805
-
-
Erickson, H.K.1
Lambert, J.M.2
-
114
-
-
84862752215
-
The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
-
Erickson HK, Phillips GD, Leipold DD et al (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 1133-1142
-
-
Erickson, H.K.1
Phillips, G.D.2
Leipold, D.D.3
-
115
-
-
84866735537
-
Pharmacokinetic considerations for antibody drug conjugates
-
Lin K, Tibbitts J (2012) Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 29:2354-2366
-
(2012)
Pharm Res
, vol.29
, pp. 2354-2366
-
-
Lin, K.1
Tibbitts, J.2
-
116
-
-
49449087300
-
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
-
Junutula JR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932
-
(2008)
Nat Biotechnol
, vol.26
, pp. 925-932
-
-
Junutula, J.R.1
Raab, H.2
Clark, S.3
-
117
-
-
33745684533
-
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
-
McDonagh CF, Turcott E,Westendorf L et al (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Design Select PEDS 19:299-307
-
(2006)
Protein Eng Design Select PEDS
, vol.19
, pp. 299-307
-
-
McDonagh, C.F.1
Turcott, E.2
Westendorf, L.3
-
118
-
-
79957730092
-
Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates
-
Zhao RY, Wilhelm SD, Audette C et al (2011) Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 54:3606-3623
-
(2011)
J Med Chem
, vol.54
, pp. 3606-3623
-
-
Zhao, R.Y.1
Wilhelm, S.D.2
Audette, C.3
-
119
-
-
84860142832
-
Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma
-
Moldenhauer G, Salnikov AV, Luttgau AV et al (2012) Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104:622-634
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 622-634
-
-
Moldenhauer, G.1
Salnikov, A.V.2
Luttgau, A.V.3
-
120
-
-
53349175018
-
Anti-CD30 diabody-drug conjugates with potent antitumor activity
-
Kim KM, McDonagh CF, Westendorf L et al (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 7:2486-2497
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2486-2497
-
-
Kim, K.M.1
McDonagh, C.F.2
Westendorf, L.3
-
121
-
-
84855577639
-
Practical theoretic guidance for the design of tumor-targeting agents
-
Wittrup KD, Thurber GM, SchmidtMMet al (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268
-
(2012)
Methods Enzymol
, vol.503
, pp. 255-268
-
-
Wittrup, K.D.1
Thurber, G.M.2
Schmidt, M.M.3
-
122
-
-
84873084305
-
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
-
Annunziata CM, Kohn EC, Lorusso P et al (2012) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 31:77-84
-
(2012)
Invest New Drugs
, vol.31
, pp. 77-84
-
-
Annunziata, C.M.1
Kohn, E.C.2
Lorusso, P.3
-
123
-
-
34247106733
-
Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC
-
Abstract 4500
-
Milowsky M, Galsky M, George M et al (2006) Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 24, Abstract 4500
-
(2006)
J Clin Oncol
, vol.24
-
-
Milowsky, M.1
Galsky, M.2
George, M.3
-
124
-
-
0037733005
-
A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma
-
Chan SY, Gordon AN, Coleman RE et al (2003) A phase 2 study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinumsensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother CII 52:243-248
-
(2003)
Cancer Immunol Immunother CII
, vol.52
, pp. 243-248
-
-
Chan, S.Y.1
Gordon, A.N.2
Coleman, R.E.3
-
125
-
-
0033752234
-
Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer
-
Gillespie AM, Broadhead TJ, Chan SY et al (2000) Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer. Ann Oncol J Eur Soc Med Oncol ESMO 11:735-741
-
(2000)
Ann Oncol J Eur Soc Med Oncol ESMO
, vol.11
, pp. 735-741
-
-
Gillespie, A.M.1
Broadhead, T.J.2
Chan, S.Y.3
|